07/08/2024 - Ocular Therapeutix Inc.: Ocular Therapeutix™ Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD

The text version of this document is not available. You can access the original document here.

Attachments

• Original Link
• Permalink

Disclaimer

Ocular Therapeutix Inc. published this content on 07 August 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 August 2024 11:04:32 UTC.